FDA Approves Tadalafil for Pulmonary Hypertension

United Therapeutics has received FDA clearance to market Adcirca, its pulmonary arterial hypertension (PAH) drug. Adcirca (tadalafil), approved as a tablet with a recommended dose of 40 mg, is the first daily phosphodiesterase type 5 inhibitor approved to treat the disease, the company says in a statement last week. United Therapeutics licensed the U.S. commercialization rights for the PAH indication for tadalafil last November from Eli Lilly, which markets the drug as Cialis for erectile dysfunction.
Washington Drug Letter